Dacia Dalla Libera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dacia Dalla Libera has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Giancarlo Comi
Department of Neurology, San Raffaele Hospital, Milan, Italy
15 shared publicationsBruno Colombo
Department of Neurology, San Raffaele Hospital, Milan, Italy
8 shared publications- Gloria Dalla Costa
Harvard School of Public Health, Harvard University, Boston, MA, USA
6 shared publications Vittorio Martinelli
6 shared publications- Roberto Furlan
Vita-Salute San Raffaele University, Milan, Italy
5 shared publications Alessandra Bergami
INSPE, Division of Neuroscience, San Raffaele Scientific Institute, Italy
4 shared publications
Latest Publications
- Open Access
- 6 December 2017
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 9 (1) , 83-84
Ayurveda: The future in the tradition
- 6 December 2017
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 9 (1) , 83-84
Open AccessAyurveda: The future in the tradition
- 19 July 2016
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 22 (11) , 1506-1508
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning
- 19 July 2016
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 22 (11) , 1506-1508
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning
- Open Access
- 12 June 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-32
Effect of extracellular vesicles derived from distinct brain cells on Aβ toxicity and assembly: focus on Microglia derived vesicles
- 12 June 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-32
Open AccessEffect of extracellular vesicles derived from distinct brain cells on Aβ toxicity and assembly: focus on Microglia derived vesicles
- 1 August 2014
- Published by Wiley in Annals of Neurology
- Vol. 76 (6) , 813-825
Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease
Objectives: We have described cerebrospinal fluid (CSF) myeloid microvesicles (MVs) as a marker of microglia activation during neuroinflammation in Alzheimer disease (AD), and characterized their ability to produce toxic amyloid β1–42 (Aβ1–42) oligomers from aggregated or soluble substrate. The aim of this study is to investigate the association of CSF myeloid MVs with neuroimaging, clinical, and paraclinical data in AD and mild cognitive impairment (MCI).Methods: We collected CSF from 106 AD patients, 51 MCI patients, and 29 neurologically healthy controls. We examined CSF myeloid MV content and AD markers. A subgroup of 34 AD and 21 MCI patients underwent structural and diffusion tensor MRI.Results: Higher levels of myeloid MVs were found in the CSF of AD patients and MCI patients converting within 3 years relative to controls, but also, at a lower level, in MCI patients not converting to AD. CSF myeloid MVs were associated with Tau but not with Aβ1–42 CSF levels. CSF MVs levels correlated with white matter (WM) tract damage in MCI, and with hippocampal atrophy in AD.Interpretation: Microglial MVs are neurotoxic and myelinotoxic in the presence of Aβ1–42. CSF myeloid MVs, mirroring microglia activation and MV release, are associated with WM damage in MCI and hippocampal atrophy in AD. This suggests that hippocampal microglia activation, in the presence of Aβ1–42 in excess, produces neurotoxic and oligodendrotoxic oligomers that, through WM tract damage, spread disease to neighboring and connected areas, causing local microglia activation and propagation of disease through the same sequence of events. Ann Neurol 2014;76:813–825
- 1 August 2014
- Published by Wiley in Annals of Neurology
- Vol. 76 (6) , 813-825
Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease
Objectives: We have described cerebrospinal fluid (CSF) myeloid microvesicles (MVs) as a marker of microglia activation during neuroinflammation in Alzheimer disease (AD), and characterized their ability to produce toxic amyloid β1–42 (Aβ1–42) oligomers from aggregated or soluble substrate. The aim of this study is to investigate the association of CSF myeloid MVs with neuroimaging, clinical, and paraclinical data in AD and mild cognitive impairment (MCI).Methods: We collected CSF from 106 AD patients, 51 MCI patients, and 29 neurologically healthy controls. We examined CSF myeloid MV content and AD markers. A subgroup of 34 AD and 21 MCI patients underwent structural and diffusion tensor MRI.Results: Higher levels of myeloid MVs were found in the CSF of AD patients and MCI patients converting within 3 years relative to controls, but also, at a lower level, in MCI patients not converting to AD. CSF myeloid MVs were associated with Tau but not with Aβ1–42 CSF levels. CSF MVs levels correlated with white matter (WM) tract damage in MCI, and with hippocampal atrophy in AD.Interpretation: Microglial MVs are neurotoxic and myelinotoxic in the presence of Aβ1–42. CSF myeloid MVs, mirroring microglia activation and MV release, are associated with WM damage in MCI and hippocampal atrophy in AD. This suggests that hippocampal microglia activation, in the presence of Aβ1–42 in excess, produces neurotoxic and oligodendrotoxic oligomers that, through WM tract damage, spread disease to neighboring and connected areas, causing local microglia activation and propagation of disease through the same sequence of events. Ann Neurol 2014;76:813–825
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e243-e244
Beyond age, the need for useful parameters to identify heart failure patients in sinus rhythm that can benefit from oral anticoagulation
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e243-e244
Beyond age, the need for useful parameters to identify heart failure patients in sinus rhythm that can benefit from oral anticoagulation
- 13 December 2013
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 21 (4) , 582-593
Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles
Alzheimer's disease (AD) is characterized by extracellular amyloid-β (Aβ) deposition, which activates microglia, induces neuroinflammation and drives neurodegeneration. Recent evidence indicates that soluble pre-fibrillar Aβ species, rather than insoluble fibrils, are the most toxic forms of Aβ. Preventing soluble Aβ formation represents, therefore, a major goal in AD. We investigated whether microvesicles (MVs) released extracellularly by reactive microglia may contribute to AD degeneration. We found that production of myeloid MVs, likely of microglial origin, is strikingly high in AD patients and in subjects with mild cognitive impairment and that AD MVs are toxic for cultured neurons. The mechanism responsible for MV neurotoxicity was defined in vitro using MVs produced by primary microglia. We demonstrated that neurotoxicity of MVs results from (i) the capability of MV lipids to promote formation of soluble Aβ species from extracellular insoluble aggregates and (ii) from the presence of neurotoxic Aβ forms trafficked to MVs after Aβ internalization into microglia. MV neurotoxicity was neutralized by the Aβ-interacting protein PrP and anti-Aβ antibodies, which prevented binding to neurons of neurotoxic soluble Aβ species. This study identifies microglia-derived MVs as a novel mechanism by which microglia participate in AD degeneration, and suggest new therapeutic strategies for the treatment of the disease.
- 13 December 2013
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 21 (4) , 582-593
Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles
Alzheimer's disease (AD) is characterized by extracellular amyloid-β (Aβ) deposition, which activates microglia, induces neuroinflammation and drives neurodegeneration. Recent evidence indicates that soluble pre-fibrillar Aβ species, rather than insoluble fibrils, are the most toxic forms of Aβ. Preventing soluble Aβ formation represents, therefore, a major goal in AD. We investigated whether microvesicles (MVs) released extracellularly by reactive microglia may contribute to AD degeneration. We found that production of myeloid MVs, likely of microglial origin, is strikingly high in AD patients and in subjects with mild cognitive impairment and that AD MVs are toxic for cultured neurons. The mechanism responsible for MV neurotoxicity was defined in vitro using MVs produced by primary microglia. We demonstrated that neurotoxicity of MVs results from (i) the capability of MV lipids to promote formation of soluble Aβ species from extracellular insoluble aggregates and (ii) from the presence of neurotoxic Aβ forms trafficked to MVs after Aβ internalization into microglia. MV neurotoxicity was neutralized by the Aβ-interacting protein PrP and anti-Aβ antibodies, which prevented binding to neurons of neurotoxic soluble Aβ species. This study identifies microglia-derived MVs as a novel mechanism by which microglia participate in AD degeneration, and suggest new therapeutic strategies for the treatment of the disease.
- 1 September 2013
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 20 (9) , 1320-1322
Parry Romberg Syndrome associated with chronic facial pain
- 1 September 2013
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 20 (9) , 1320-1322
Parry Romberg Syndrome associated with chronic facial pain
- 8 July 2013
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 20 (2) , 147-155
Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes
Background: Growing evidence suggests that vitamin D deficiency may be one of the most important environmental factors for the development of multiple sclerosis (MS). Objectives: The objectives of this paper are to evaluate serum 25-hydroxyvitamin D (25(OH)D) levels in patients with clinically isolated syndromes (CIS) and to examine whether they are related to MS risk. Methods: This is a retrospective study of 100 CIS patients hospitalized from 2000 to 2009 at San Raffaele Hospital, Milan, Italy. We evaluated baseline 25(OH)D level as well as clinical, brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. Results: A total of 52% of CIS patients had vitamin D deficiency (25(OH)D < 50 nmol/l). During follow-up (median: 7.17 years), 55 patients developed clinically definite MS (CDMS). Patients with very low (< 10th percentile) and low (< 25th percentile) 25(OH)D levels were particularly at risk of CDMS (HRs (95% CIs): 2.12 (0.91–4.96) and 1.61 (0.85–3.03), respectively), while no further reduction in the HRs of disease was observed at high levels of 25(OH)D. This association was even stronger after adjustment for additional risk factors for CDMS development (HRs (95% CIs) for 25(OH)D levels < 10th and 25th percentiles: 3.34 (1.32–8.45) and 2.04 (0.96–4.36), respectively). Conclusion: Low serum vitamin D is associated with increased MS risk in patients with CIS.
- 8 July 2013
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 20 (2) , 147-155
Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes
Background: Growing evidence suggests that vitamin D deficiency may be one of the most important environmental factors for the development of multiple sclerosis (MS). Objectives: The objectives of this paper are to evaluate serum 25-hydroxyvitamin D (25(OH)D) levels in patients with clinically isolated syndromes (CIS) and to examine whether they are related to MS risk. Methods: This is a retrospective study of 100 CIS patients hospitalized from 2000 to 2009 at San Raffaele Hospital, Milan, Italy. We evaluated baseline 25(OH)D level as well as clinical, brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. Results: A total of 52% of CIS patients had vitamin D deficiency (25(OH)D < 50 nmol/l). During follow-up (median: 7.17 years), 55 patients developed clinically definite MS (CDMS). Patients with very low (< 10th percentile) and low (< 25th percentile) 25(OH)D levels were particularly at risk of CDMS (HRs (95% CIs): 2.12 (0.91–4.96) and 1.61 (0.85–3.03), respectively), while no further reduction in the HRs of disease was observed at high levels of 25(OH)D. This association was even stronger after adjustment for additional risk factors for CDMS development (HRs (95% CIs) for 25(OH)D levels < 10th and 25th percentiles: 3.34 (1.32–8.45) and 2.04 (0.96–4.36), respectively). Conclusion: Low serum vitamin D is associated with increased MS risk in patients with CIS.
- 22 May 2013
- Published by Springer Nature in Neurological Sciences
- Vol. 34 (S1) , 109-112
Refractory migraine: the role of the physician in assessment and treatment of a problematic disease
Patients affected by chronic forms of headache are often very difficult to treat. Refractory patients are so defined when adequate trials of specific drugs (for acute or prophylactic treatment) failed both to reduce the burden of disease and to improve headache-related quality of life. An escalating approach is suggested to test different kinds of therapies. All comorbid factors should be addressed. More invasive modalities (such as neurostimulation) or promising approaches such as repetitive transcranial magnetic stimulation (rTMS) could be a future major step as third line therapies.
- 22 May 2013
- Published by Springer Nature in Neurological Sciences
- Vol. 34 (S1) , 109-112
Refractory migraine: the role of the physician in assessment and treatment of a problematic disease
Patients affected by chronic forms of headache are often very difficult to treat. Refractory patients are so defined when adequate trials of specific drugs (for acute or prophylactic treatment) failed both to reduce the burden of disease and to improve headache-related quality of life. An escalating approach is suggested to test different kinds of therapies. All comorbid factors should be addressed. More invasive modalities (such as neurostimulation) or promising approaches such as repetitive transcranial magnetic stimulation (rTMS) could be a future major step as third line therapies.
- 24 April 2013
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 53 (5) , 843-844
The Portrayal of Migraine in I talian Popular Music
- 24 April 2013
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 53 (5) , 843-844
The Portrayal of Migraine in I talian Popular Music